Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model

被引:0
|
作者
Z Li
A Rakkar
Y Katayose
M Kim
N Shanmugam
S Srivastava
JW Moul
DG McLeod
KH Cowan
P Seth
机构
[1] Medical Breast Cancer Section,Department of Surgery
[2] Medicine Branch,undefined
[3] National Cancer Institute,undefined
[4] National Institutes of Health,undefined
[5] Center for Prostate Disease Research,undefined
[6] USUHS,undefined
来源
Gene Therapy | 1998年 / 5卷
关键词
adenovirus; p53; gene therapy; apoptosis; bystander effect;
D O I
暂无
中图分类号
学科分类号
摘要
Infection of Renca cells in vitro with a recombinant adenovirus expressing a marker gene β-galactosidase resulted in high level of the transgene expression. Renca tumors grown in Balb/C mice were also infectable with this recombinant adenovirus. The transgene expression in the tumors lasted for about 7 days, however, administration of another dose of Ad-βgal, on day 7 produced β-galactosidase expression. To investigate the effect of antibodies to adenovirus, animals were injected with multiple doses of adenovirus to produce neutralizing antibodies. To these animals Renca cells were injected and tumors formed. Interestingly, when Adβ-gal was administered into these tumors, a high level of transgene expression was still observed. We next explored the utility of a recombinant adenovirus expressing p53 (AdWTp53) in the Renca tumor model. Renca cells when exposed to an adenovirus expressing p53 (AdWTp53) produced a high level of p53 protein, a p53-inducible gene p21/WAF1/Cip1 and underwent apoptosis. A single injection of AdWTp53 (109 plaque forming units) resulted in significant inhibition of tumor growth. However, multiple administrations (four doses of 2.5 × 108 plaque forming units) of AdWTp53 were needed for tumor cures. Mixing uninfected and AdWTp53-infected cells showed a bystander effect of AdWTp53-infected Renca cells. Based on these results we believe that an appropriate dose scheduling of AdWTp53 can be efficacious for cancer gene therapy in immune-competent tumor-bearing animals.
引用
收藏
页码:605 / 613
页数:8
相关论文
共 50 条
  • [1] Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model
    Li, Z
    Rakkar, A
    Katayose, Y
    Kim, M
    Shanmugam, N
    Srivastava, S
    Moul, JW
    McLeod, DG
    Cowan, KH
    Seth, P
    GENE THERAPY, 1998, 5 (05) : 605 - 613
  • [2] Multiple administration of a recombinant adenovirus encoding wild-type p53: Tumor suppression in an immunocompetent mouse model
    Zepeda, M
    Kang, D
    Neugebauer, S
    Demers, B
    Maneval, DC
    CANCER GENE THERAPY, 1998, 5 (06) : S27 - S27
  • [3] Recombinant adenovirus expressing wild-type p53 is antiangiogenic:: A proposed mechanism for bystander effect
    Nishizaki, M
    Fujiwara, T
    Tanida, T
    Hizuta, A
    Nishimori, H
    Tokino, T
    Nakamura, Y
    Bouvet, M
    Roth, JA
    Tanaka, N
    CLINICAL CANCER RESEARCH, 1999, 5 (05) : 1015 - 1023
  • [4] Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)
    Nancy Yen
    Constantin G Ioannides
    Kai Xu
    Stephen G Swisher
    David D Lawrence
    Bonnie L Kemp
    Adel K El-Naggar
    Richard J Cristiano
    Bingliang Fang
    Bonnie S Glisson
    Waun K Hong
    Fadlo R Khuri
    Jonathan M Kurie
    J Jack Lee
    Jin S Lee
    James A Merritt
    Tapas Mukhopadhyay
    Jonathan C Nesbitt
    Dao Nguyen
    Roman Perez-Soler
    Katherine M W Pisters
    Joe B Putnam
    David S Schrump
    Dong M Shin
    Garrett L Walsh
    Jack A Roth
    Cancer Gene Therapy, 2000, 7 : 530 - 536
  • [5] Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)
    Yen, N
    Ioannides, CG
    Xu, K
    Swisher, SG
    Lawrence, DD
    Kemp, BL
    El-Naggar, AK
    Cristiano, RJ
    Fang, BL
    Glisson, BS
    Hong, WK
    Khuri, FR
    Kurie, JM
    Lee, JJ
    Lee, JS
    Merritt, JA
    Mukhopadhyay, T
    Nesbitt, JC
    Nguyen, D
    Perez-Soler, R
    Pisters, KMW
    Putnam, JB
    Schrump, DS
    Shin, DM
    Walsh, GL
    Roth, JA
    CANCER GENE THERAPY, 2000, 7 (04) : 530 - 536
  • [6] Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
    Li, PX
    Bui, T
    Gray, D
    Klamut, HJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 48 (03) : 273 - 286
  • [7] Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
    Peixiang Li
    Thuy Bui
    Dawn Gray
    Henry J. Klamut
    Breast Cancer Research and Treatment, 1998, 48 : 273 - 286
  • [8] Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas
    Song, KM
    Li, ZW
    Seth, P
    Cowan, KH
    Sinha, BK
    ONCOLOGY RESEARCH, 1997, 9 (11-12) : 603 - 609
  • [9] RECOMBINANT ADENOVIRUS VECTOR EXPRESSING WILD-TYPE P53 IS A POTENT INHIBITOR OF PROSTATE-CANCER CELL-PROLIFERATION
    SRIVASTAVA, S
    KATAYOSE, D
    TONG, YA
    CRAIG, CR
    MCLEOD, DG
    MOUL, JW
    COWAN, KH
    SETH, P
    UROLOGY, 1995, 46 (06) : 843 - 848
  • [10] Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53
    Gjerset, RA
    Turla, ST
    Sobol, RE
    Scalise, JJ
    Mercola, D
    Collins, H
    Hopkins, PJ
    MOLECULAR CARCINOGENESIS, 1995, 14 (04) : 275 - 285